BIOMARKER:

CD163 overexpression

Entrez ID:

Related biomarkers:

‹

›

CD163 overexpression CD163 overexpression	Hodgkin Lymphoma HL	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
CD163 overexpression CD163 overexpression	Solid Tumor Solid Tumor	avelumab + IMP 321 Sensitive: C3 – Early Trials
CD163 overexpression CD163 overexpression	Solid Tumor Solid Tumor	IMP 321 Sensitive: C3 – Early Trials

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

Associations